Abstract Eribulin was evaluated in angiosarcoma and epithelioid hemangioendothelioma through two prospective international trials. While encouraging activity was observed in EHE, its role in angiosarcoma may depend on further refinement through subgroup selection. These findings underscore the importance of histology-specific interpretation, innovative endpoints, and coordinated strategies for ultra-rare sarcoma drug development.
Tom Wei‐Wu Chen (Thu,) studied this question.